Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioXtreme is an Israeli rehabilitation robotics company developing neurorehabilitation devices for stroke and other neurological injuries. Its core approach is a patented Error Enhancement technology that uses robotic force application, adaptive algorithms, and virtual-reality-based therapy to accelerate motor recovery without relying primarily on cognitive compensation strategies. The company’s lead systems include deXtreme for upper-limb post-stroke rehabilitation and plaXtreme for palm and finger rehabilitation in patients with stroke, traumatic brain injury, and related neurological conditions. BioXtreme reports completed clinical studies for deXtreme, ongoing or recent clinical work for plaXtreme, and commercial/distribution activity in Europe, North America, and Southeast Asia. The business appears to operate as a private medtech company rather than a drug developer, with a focus on robotic neurotherapy systems for rehabilitation centers and hospitals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioXtreme.